Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
AL Amyloidosis: early-phase trial registry
7 of 16 indexed AL Amyloidosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 7 currently recruiting · #1,060 of 28,707 conditions by registered trial count
AL Amyloidosis: 16 US clinical trials tracked, 7 recruiting.
AL Amyloidosis is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Alexion Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition al-amyloidosis
OPEN 7 | RECR 44% | LATE 4 | EARLY 10 | RANK #1060 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Distress Syndrome (44% recruiting · 32 trials)
AL Amyloidosis lists 7 open slots (44% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for AL Amyloidosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
AL Amyloidosis is recruiting below its size-band peers.
7 of 16 indexed trials (43.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of AL Amyloidosis trials is spread across many organizations.
Alexion Pharmaceuticals accounts for 2 of 16 trials (12.5%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most AL Amyloidosis trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 16 trials that report a genuine target (sentinel values excluded). 11 of those (68.8%) plan for fewer than 100 participants.
-
AL Amyloidosis research is mostly interventional.
14 interventional and 2 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Ohio State University Comprehensive Cancer Center
NCT01408225
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
SWOG Cancer Research Network
NCT06022939
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Life Molecular Imaging
NCT05184088
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Mayo Clinic
NCT05898646
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Rajshekhar Chakraborty, MD
NCT05451771
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Brigham and Women's Hospital
NCT06569147
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
NCT05145816
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals
NCT04512235
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Alexion Pharmaceuticals
NCT04504825
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
NCT03315026
Ixazomib Maintenance Study in Patients With AL Amyloidosis
Memorial Sloan Kettering Cancer Center
NCT03618537
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
NCT04270175
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Emory University
NCT04754945
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Columbia University
NCT01222260
Radioimmunoimaging of AL Amyloidosis
University of Tennessee
NCT01409148
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
The Cleveland Clinic
NCT03431896
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 5 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on AL Amyloidosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on AL Amyloidosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this AL Amyloidosis page
16 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 AL Amyloidosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alexion Pharmaceuticals sponsors the most AL Amyloidosis trials on record, review their full trial history before evaluating a specific study. See Alexion Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This AL Amyloidosis condition card totals 16 registered trials; most-linked intervention Dexamethasone; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.